Where Will Recursion Pharmaceuticals Be in 5 Years? [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
Rather than simply making drugs alone, its business model features additional elements like renting out access to its data and being a capable collaborator for other biopharmas looking to discover new medicines. Presently, it's still in its infancy. Its plans are in motion, but they'll take quite some time to pay off. So where will Recursion be in five years, and is the stock worth buying today? There's a lot coming up Today, Recursion has no products approved for sale. By early 2029, it could have as many as five medicines on the market, marking a relatively rapid transition from fledgling biotech stock to a more mature one. All five of those are currently in phase 2 clinical trials, and three of them are for rare diseases like cerebral cavernous malformation (CCM) or neurofibromatosis type 2 (NF2). For reference, CCM affects around 360,000 people across the U.S., U.K., Italy, France, Spain, and Germany, whereas NF2 affects 33,000 across the same set of countries. If the biot
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering ProgramGlobeNewswire
- Nvidia Owns a 3.4% Stake in This Innovative Artificial Intelligence (AI) Stock Cathie Wood Loves [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial OfficerGlobeNewswire
RXRX
Earnings
- 2/27/24 - Beat
RXRX
Sec Filings
- 4/29/24 - Form 4
- 4/25/24 - Form 3
- 4/25/24 - Form 144
- RXRX's page on the SEC website